Journal profile · ONCOLOGY-OBSTETRICS & GYNECOLOGY
Breast Cancer
ISSN 1340-6868 · eISSN 1880-4233 · Springer Japan · JAPAN · 6 issues per year · Founded 1994
Breast Cancer: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.64; hybrid open access; APC about USD 3,890; median 118 days to acceptance (94 articles, last 24 months); community-reported acceptance: easy; 148 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Breast Cancer is published by Springer Japan and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Breast Lesions and Carcinomas and Breast Implant and Reconstruction, together about 45.8% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Breast Cancer, the official journal of the Japanese Breast Cancer Society, publishes articles that contribute to progress in the field, in basic or translational research and also in clinical research, seeking to develop a new focus and new perspectives for all who are concerned with breast cancer. The journal welcomes all original articles describing clinical and epidemiological studies and laboratory investigations regarding breast cancer and related diseases. The journal will consider five types of articles: editorials, review articles, original articles, case reports, and rapid communications. Although editorials and review articles will principally be solicited by the editors, they can also be submitted for peer review, as in the case of original articles. The journal provides the best of up-to-date information on breast cancer, presenting readers with high-impact, original work focusing on pivotal issues.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY-OBSTETRICS & GYNECOLOGY
Editor-in-chief Takayuki UenoPublisher website
Editorial board by country: none in mainland China; most named Japan 31, United States 6, South Korea 4, United Kingdom 3, Australia 2 (50 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology24.4%
- Breast Lesions and CarcinomasMedicine14.3%
- Breast Implant and ReconstructionMedicine7.1%
- HER2/EGFR in Cancer ResearchMedicine5.8%
- Cancer Treatment and PharmacologyMedicine4.3%
- Estrogen and related hormone effectsBiochemistry, Genetics and Molecular Biology4%
- Advanced Breast Cancer TherapiesMedicine3.9%
- BRCA gene mutations in cancerBiochemistry, Genetics and Molecular Biology3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Obstetrics & Gynecology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Obstetrics & Gynecology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Obstetrics & Gynecology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.64LetPub ·
- Impact factor (publisher) 2025
- 3.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.6Publisher website ·
- CiteScore 2026-06
- 5.4LetPub ·
- SJR 2026-06
- 1.04LetPub ·
- SNIP 2026-06
- 1.1LetPub ·
- h-index
- 47LetPub ·
- h-index
- 83OpenAlex ·
- i10-index
- 1,477OpenAlex ·
- 2-year mean citedness
- 2.97OpenAlex ·
- Self-citation rate
- 8.1%LetPub ·
- Share of gold OA articles
- 41.55%LetPub ·
Volume
- Articles per year
- 131LetPub ·
- Downloads per year (publisher) 2025
- 654,600Publisher website ·
Articles by year OpenAlex count · 3,483 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 149 | 97 | 28 |
| 2025 | 148 | 70 | 273 |
| 2024 | 155 | 54 | 1,040 |
| 2023 | 108 | 58 | 867 |
| 2022 | 159 | 61 | 1,997 |
| 2021 | 149 | 60 | 2,195 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
118 daysMedian, submission to acceptance · P25–P75 79 days – 174 days
- Acceptance to online
- median 14 days (94 articles)
- Submission to online
- median 133 days
- Sample
- 94 articles with submission and acceptance dates (282 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Submission to first decision
- 9 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,890 / EUR 2,990 / GBP 2,590 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted9, with length limits
- case reportAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…Length not stated
- editorialAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…main text ≤ 1,000 words
- letterAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…Length not stated
- letter to the editorLetters to the Editor commenting on articles published previously in the journal or expressing views on topics relevant to breast cancer will be published at th…Length not stated
- letters to the editorAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…Length not stated
- opinionAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…Length not stated
- original articleAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…Length not stated
- rapid communicationAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…main text ≤ 2,000 words
- review articleAll manuscripts should be divided into the following sections: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials and Methods (or Patients and Method…main text ≤ 4,000 words
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Potential conflict of interest
All authors are required to disclose any financial relationship with a biotechnology manufacturer, pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. Readers are entitled to transparency regarding any real or perceived conflicts of interest. This is not meant to imply that a financial relationship with an organiza…
Source ↗Publisher website ·- Data availability
Data transparency Model summary
All authors are requested to make sure that all data and materials as well as software application or custom code support their published claims and comply with field standards.
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
COPE member, research integrity Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright
Copyright permission required Model summary
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers.
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Breast Cancer, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review
Single-blind peer review Model summary
This journal follows a single-blind reviewing procedure.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
Clinical trial registration required Model summary
Breast Cancer adopts ICMJE's policy regarding clinical trial registration (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html). Specifically, Breast Cancer requires registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition of consideration for publication. Breast Cancer foll…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Japan
- Country or region
- JAPAN
- Language
- English
- Frequency
- 6 issues per year
- Founded
- 1994
- ISSN
- 1340-6868
- Electronic ISSN
- 1880-4233
- Society / sponsor
- Japanese Breast Cancer Society
- Latest issue on the website
- Volume 33, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Breast Cancer
What CAS zone is Breast Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Breast Cancer is in Zone 3 of Medicine, and in Zone 3 of the minor category Obstetrics & Gynecology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Breast Cancer?
The latest impact factor listed by LetPub is 3.64; CiteScore 5.4, h-index 83.
How long does peer review take at Breast Cancer?
Based on the dates recorded on 94 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 118 days (interquartile range 79–174 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Breast Cancer based?
Of the 50 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Japan (31), United States (6) and South Korea (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Breast Cancer?
According to LetPub and DOAJ records, Breast Cancer is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and Current Contents; that list has not been checked against each database.
Is Breast Cancer open access, and what is the APC?
Breast Cancer is a hybrid journal. For open-access publication: APC about USD 3,890.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .